多参数磁共振靶向活检与系统经直肠超声活检在前列腺癌风险初筛男性中的比较:3期随机临床试验
这项多中心3期随机试验纳入453例未活检且临床怀疑前列腺癌的男性,比较仅MRI靶向活检与12针系统TRUS活检对GG2及以上前列腺癌的检出。MRI靶向组检出率35%对30%,绝对差5%,达到非劣效界值-5%。MRI组避免了37%的活检,GG1癌检出减半,不良事件更少。
要点
- MRI靶向活检对GG2及以上前列腺癌检出非劣效于系统TRUS活检。
- MRI组37%因阴性MRI避免活检,GG1癌检出从22%降至10%。
- MRI靶向组不良事件更少,支持以MRI先行策略。
核心结论
- 在未活检且临床怀疑前列腺癌的男性中,仅MRI靶向活检对GG2及以上前列腺癌的检出非劣效于初始系统TRUS活检。
研究设计与样本
- 多中心前瞻性随机临床试验,2017年1月至2019年11月在5个加拿大学术健康科学中心开展,纳入453例未活检且临床怀疑前列腺癌的男性。
- 临床怀疑定义为PCPTRC v2.0计算GG2及以上前列腺癌风险≥5%,且血清PSA≤20 ng/mL、无MRI禁忌。
- 意向治疗人群453例随机接受TRUS活检(226例)或MRI-TB(227例),421例(93.0%)可方案评估。
主要发现
- TRUS组225例中67例(30%)检出GG2及以上癌,MRI-TB组227例中79例(35%)检出,绝对差5%,97.5%单侧CI -3.4%至∞,非劣效界值-5%。
- 221例接受MRI者中138例(62.4%)检出PI-RADS≥3病灶,最大PI-RADS评分3、4、5分别26例(12.1%)、82例(38.1%)、30例(14.0%)。
- MRI组GG1癌检出从22%降至10%,风险差-11.6%(95%CI -18.2%至-4.9%)。
- MRI-TB组不良事件较TRUS组更少见。
临床怎么用
- 对未活检且临床怀疑前列腺癌的男性,可先行多参数MRI,仅对PI-RADS≥3病灶行靶向活检,以减少系统活检和低级别癌检出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Magnetic resonance imaging (MRI) with targeted biopsy is an appealing alternative to systematic 12-core transrectal ultrasonography (TRUS) biopsy for prostate cancer diagnosis, but has yet to be widely adopted. OBJECTIVE: To determine whether MRI with only targeted biopsy was noninferior to systematic TRUS biopsies in the detection of International Society of Urological Pathology grade group (GG) 2 or greater prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, prospective randomized clinical trial was conducted in 5 Canadian academic health sciences centers between January 2017 and November 2019, and data were analyzed between January and March 2020. Participants included biopsy-naive men with a clinical suspicion of prostate cancer who were advised to undergo a prostate biopsy. Clinical suspicion was defined as a 5% or greater chance of GG2 or greater prostate cancer using the Prostate Cancer Prevention Trial Risk Calculator, version 2. Additional criteria were serum prostate-specific antigen levels of 20 ng/mL or less (to convert to micrograms per liter, multiply by 1) and no contraindication to MRI. INTERVENTIONS: Magnetic resonance imaging-targeted biopsy (MRI-TB) only if a lesion with a Prostate Imaging Reporting and Data System (PI-RADS), v 2.0, score of 3 or greater was identified vs 12-core systematic TRUS biopsy. MAIN OUTCOME AND MEASURES: The proportion of men with a diagnosis of GG2 or greater cancer. Secondary outcomes included the proportion who received a diagnosis of GG1 prostate cancer; GG3 or greater cancer; no significant cancer but subsequent positive MRI results and/or GG2 or greater cancer detected on a repeated biopsy by 2 years; and adverse events. RESULTS: The intention-to-treat population comprised 453 patients (367 [81.0%] White, 19 [4.2%] African Canadian, 32 [7.1%] Asian, and 10 [2.2%] Hispanic) who were randomized to undergo TRUS biopsy (226 [49.9%]) or MRI-TB (227 [51.1%]), of which 421 (93.0%) were evaluable per protocol. A lesion with a PI-RADS score of 3 or greater was detected in 138 of 221 men (62.4%) who underwent MRI, with 26 (12.1%), 82 (38.1%), and 30 (14.0%) having maximum PI-RADS scores of 3, 4, and 5, respectively. Eighty-three of 221 men who underwent MRI-TB (37%) had a negative MRI result and avoided biopsy. Cancers GG2 and greater were identified in 67 of 225 men (30%) who underwent TRUS biopsy vs 79 of 227 (35%) allocated to MRI-TB (absolute difference, 5%, 97.5% 1-sided CI, -3.4% to ∞; noninferiority margin, -5%). Adverse events were less common in the MRI-TB arm. Grade group 1 cancer detection was reduced by more than half in the MRI arm (from 22% to 10%; risk difference, -11.6%; 95% CI, -18.2% to -4.9%). CONCLUSIONS AND RELEVANCE: Magnetic resonance imaging followed by selected targeted biopsy is noninferior to initial systematic biopsy in men at risk for prostate cancer in detecting GG2 or greater cancers. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02936258.
引用
- Klotz L, Chin J, Black PC, et al. Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33538782. doi:10.1001/jamaoncol.2020.7589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。